PPCB — Propanc Biopharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1517681 ·
Last close
$1.15
Market Cap
$2.63M
52W High
$6.79
52W Low
$0.95
ADV30
132,410
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -6,400,221 | -6,360,336 | 14,333,780 | 443,702 | 3,505,895 |
| Dec 2025 | 0 | — | -3,654,734 | -3,091,394 | 15,111,532 | 561,237 | 3,659,267 |
| Sep 2025 | 0 | — | -4,673,564 | -4,837,738 | 17,975,681 | 602,737 | 3,614,514 |
| Jun 2025 | 0 | — | -3,645,246 | -4,071,461 | 19,631,808 | 12,088 | 5,725,616 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-4,107,839
Investing CF
$-4,912
Financing CF
$4,481,241
CapEx
$-4,912
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-20.19
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-140,843,234
Inventory
—
Receivables
$11,057
ST Investments
—
EBIT TTM
$-17,703,513
Pretax Income TTM
$-18,360,929
Interest Exp TTM
$657,416
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | — | — | — | — | — | — | — |
| Jun 2024 | 0 | -1,536,049 | -1,820,528 | 72,400 | 3,851,424 | — | -935,118 |
| Jun 2023 | 0 | -1,776,645 | -2,660,566 | 60,300 | 3,177,507 | — | -1,105,251 |
| Jun 2022 | 0 | -1,990,870 | -2,658,087 | 81,651 | 3,105,300 | — | -1,436,304 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CASIF | CASI Pharmaceuticals, Inc. | $2.65M | $0.13 | — |
| ONCO | Onconetix, Inc. | $2.59M | $0.66 | — |
| NXTS | Nexentis Technologies Inc. | $2.59M | $1.78 | — |
| ACUT | Accustem Sciences Inc. | $2.57M | $0.16 | — |
| PPBT | PURPLE BIOTECH LTD. | $2.54M | $1.56 | — |
News headlines (Yahoo Finance, 1h cache)
Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models
2026-08-06 12:30 · Yahoo
Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program
2026-08-05 12:30 · Yahoo
Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal
2026-07-21 12:30 · Yahoo
Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd
2026-07-07 12:30 · Yahoo
Propanc Biopharma Initiates $5.0 Million Share Repurchase Program
2026-07-02 12:30 · Yahoo
Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study
2026-06-16 12:45 · Yahoo
Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program
2026-06-11 12:30 · Yahoo
Propanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain
2026-06-02 09:30 · Yahoo
Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients
2026-05-19 12:45 · Yahoo
Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
2026-05-15 12:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.